CFTR Polynucleotide Lipid Formulations for Targeted Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cells have limited uptake of exogenous nucleic acids, leading to inefficient protein expression and potential immune system interference, and existing chemotherapeutic agents exhibit significant cytotoxicity without targeted organ delivery.
Innovation Solution
A synthetic polynucleotide encoding CFTR protein, formulated with a lipid composition comprising an ionizable cationic lipid and a selective organ targeting (SORT) lipid, is delivered to lung cells to enhance CFTR protein expression and activity, using aerosol compositions for targeted pulmonary delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If exogenous nucleic acids are delivered to cells, then protein expression can be achieved, but cellular uptake is limited and immune system interference occurs
Solution Approach 1:
The patent modifies the nucleic acid sequence parameters by incorporating pseudouridine substitutions and optimizing codon usage to reduce immune recognition while maintaining protein expression efficiency. This chemical modification changes the physical-chemical properties of the nucleic acid to evade immune detection.
Solution Approach 2:
The patent uses lipid nanoparticles as an intermediary delivery vehicle to protect the nucleic acid from immune system interference during delivery. The lipid nanoparticle carrier mediates the delivery process, shielding the therapeutic nucleic acid from immune recognition while facilitating cellular uptake.
2Reliability
If chemotherapeutic agents are used to treat disease, then therapeutic effect is achieved, but significant cytotoxicity and off-target effects occur
Solution Approach 1:
The patent incorporates selective organ targeting (SORT) lipid components that direct the nucleic acid delivery specifically to lung tissue and pulmonary epithelial cells. This localized delivery ensures the therapeutic effect is concentrated where needed while minimizing exposure and harmful effects in other organs.
Solution Approach 2:
The patent uses a composite lipid nanoparticle formulation combining ionizable cationic lipids, neutral lipids, and SORT lipids. This composite material provides both efficient cellular delivery and targeted organ specificity, achieving therapeutic effects while reducing off-target cytotoxicity through the synergistic properties of the composite structure.
Data Source
AI summary
Compositions of polynucleotide(s), pharmaceutical compositions thereof, and methods of use thereof are disclosed. A polynucleotide may encode for a cystic fibrosis transmembrane conductance regulator (CFTR) protein or a functional fragment thereof. The polynucleotide may be assembled with a lipid composition for targeted delivery to a cell or an organ, such as a lung cell or a lung of a subject. Methods for enhancing an expression or activity of CFTR protein in a cell are provided. Methods for treating a subject having or suspected of having a CFTR-associated condition are also provided.